Oral administration, usually with or after food to minimize gastrointestinal discomfort.

Nimesulide acts primarily as a preferential inhibitor of cyclooxygenase-2 (COX-2), an enzyme involved in the synthesis of prostaglandins. By inhibiting COX-2, it reduces the production of inflammatory prostaglandins, thereby exerting its anti-inflammatory, analgesic, and antipyretic effects.

• •History of hypersensitivity to nimesulide or other NSAIDs
• •Active gastrointestinal bleeding or peptic ulcer
• •Severe hepatic impairment
• •Severe renal impairment (creatinine clearance < 30 mL/min)
• •Children under 12 years of age
• •Pregnancy (especially third trimester) and lactation
• •History of bronchospasm, rhinitis, or urticaria following aspirin or other NSAID administration

Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children. Do not freeze.

Symptoms of overdose may include drowsiness, lethargy, nausea, vomiting, epigastric pain, and gastrointestinal bleeding. Rare cases of hypertension, acute renal failure, anaphylactoid reactions, and respiratory depression have been reported. Management involves symptomatic and supportive treatment. Gastric lavage and/or activated charcoal may be considered if ingested recently. There is no specific antidote.

Nimesulide is contraindicated during the third trimester of pregnancy due to potential adverse effects on the fetus (e.g., premature closure of the ductus arteriosus). It is generally not recommended during other trimesters or during lactation, as it may pass into breast milk and pose risks to the infant.